Hesperidin methylchalcone structure
|
Common Name | Hesperidin methylchalcone | ||
|---|---|---|---|---|
| CAS Number | 24292-52-2 | Molecular Weight | 624.587 | |
| Density | 1.6±0.1 g/cm3 | Boiling Point | 953.0±65.0 °C at 760 mmHg | |
| Molecular Formula | C29H36O15 | Melting Point | 120 °C (dec.)(lit.) | |
| MSDS | Chinese USA | Flash Point | 309.5±27.8 °C | |
Use of Hesperidin methylchalconeHesperidin methylchalcone (Hesperidin methyl chalcone) inhibits oxidative stress, cytokine production and NF-κB activation. Hesperidin methylchalcone inhibits inflammation and pain. Hesperidin methylchalcone exhibits vasoprotective activity[1]. |
| Name | Hesperidin methylchalcone |
|---|---|
| Synonym | More Synonyms |
| Description | Hesperidin methylchalcone (Hesperidin methyl chalcone) inhibits oxidative stress, cytokine production and NF-κB activation. Hesperidin methylchalcone inhibits inflammation and pain. Hesperidin methylchalcone exhibits vasoprotective activity[1]. |
|---|---|
| Related Catalog | |
| Target |
NF-κB |
| References |
| Density | 1.6±0.1 g/cm3 |
|---|---|
| Boiling Point | 953.0±65.0 °C at 760 mmHg |
| Melting Point | 120 °C (dec.)(lit.) |
| Molecular Formula | C29H36O15 |
| Molecular Weight | 624.587 |
| Flash Point | 309.5±27.8 °C |
| Exact Mass | 624.205444 |
| PSA | 234.29000 |
| LogP | 1.86 |
| Vapour Pressure | 0.0±0.3 mmHg at 25°C |
| Index of Refraction | 1.672 |
| InChIKey | FDHNLHLOJLLXDH-JIYHLSBYSA-N |
| SMILES | COc1ccc(C=CC(=O)c2c(O)cc(OC3OC(COC4OC(C)C(O)C(O)C4O)C(O)C(O)C3O)cc2OC)cc1O |
| Storage condition | 2-8℃ |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| RIDADR | NONH for all modes of transport |
| WGK Germany | 3 |
| RTECS | FL7085000 |
|
Assessment of the antineoplastic potential of chalcones in animal models.
Curr. Med. Chem. 20(2) , 186-221, (2013) One part of chemical space that is endowed with interesting biological properties is the area of the chalcones. With this review, we provide a comprehensive overview of the numerous in vivo animal stu... |
|
|
Absorption and elimination of (14C) hesperidin methylchalcone in the rat.
Eur. J. Drug Metab. Pharmacokinet. 6(3) , 171-7, (1981) Hesperidin methylchalcone resorption and excretion were studied in rats, using 14C-labelling. The level of radioactivity in the blood showed a peak 1-2 hours after oral administration of the labelled ... |
|
|
Inhibitory effect of the Ruscus extract and of the flavonoid hesperidine methylchalcone on increased microvascular permeability induced by various agents in the hamster cheek pouch.
J. Cardiovasc. Pharmacol. 22(2) , 225-30, (1993) The Ruscus extract and the flavonoid hesperidine methylchalcone (HMC) are used in treatment of venous insufficiency. In the present study, we used the hamster cheek pouch preparation and investigated ... |
| 2-Propen-1-one, 1-[4-[[6-O-(6-deoxy-α-L-mannopyranosyl)-β-D-glucopyranosyl]oxy]-2-hydroxy-6-methoxyphenyl]-3-(3-hydroxy-4-methoxyphenyl)- |
| 3-Hydroxy-4-[3-(3-hydroxy-4-methoxyphenyl)acryloyl]-5-methoxyphenyl 6-O-(6-deoxy-α-L-mannopyranosyl)-β-D-glucopyranoside |
| HESPERIDIN METHYL CHALCONE |
| HESPERIDIN METHYL CHALCONE*PRACTICAL GRA DE |
| EINECS 246-128-2 |
| MFCD00010438 |
| Hesperidine Methyl Chalcone |
| (e)-osyl]oxy]-2-hydroxy-6-methoxyphenyl]-3-(3-hydroxy-4-methoxyphenyl) |